Update and new approaches in the treatment of Castleman disease
AuthorChan, K-L; Lade, S; Prince, HM; Harrison, SJ
Source TitleJournal of Blood Medicine
PublisherDOVE MEDICAL PRESS LTD
AffiliationSir Peter MacCallum Department of Oncology
Medicine (St Vincent's)
Document TypeJournal Article
CitationsChan, K. -L., Lade, S., Prince, H. M. & Harrison, S. J. (2016). Update and new approaches in the treatment of Castleman disease. JOURNAL OF BLOOD MEDICINE, 7, pp.145-158. https://doi.org/10.2147/JBM.S60514.
Access StatusOpen Access
First described 60 years ago, Castleman disease comprises a rare and heterogeneous cluster of disorders, characterized by lymphadenopathy with unique histological features and associated with cytokine-driven constitutional symptoms and biochemical disturbances. Although unicentric Castleman disease is curable with complete surgical excision, its multicentric counterpart is a considerable therapeutic challenge. The recent development of biological agents, particularly monoclonal antibodies to interleukin-6 and its receptor, allow for more targeted disease-specific intervention that promises improved response rates and more durable disease control; however, further work is required to fill knowledge gaps in terms of underlying pathophysiology and to facilitate alternative treatment options for refractory cases.
- Click on "Export Reference in RIS Format" and choose "open with... Endnote".
- Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References